Aziza Alrafiah1,2 , Zaher M.A.F3, Khloud Algothmi4, Khlood Mehdar5, Saad Misfer Alqahtani6, Khuzama Al-Ammari1
1Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University; 2Princess Dr. Najla Al Saud Center for Research Excellence in Biotechnology, King Abdulaziz University, Jeddah; 3Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah; 4Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah; 5Department of Anatomy, College of Medicine, Najran University; 6Department of Pathology, College of Medicine, The University Hospital, Najran University, Najran, Saudi Arabia.For correspondence:- Aziza Alrafiah Email: aalrafiah@kau.edu.sa
Received: 10 April 2024 Accepted: 3 October 2024 Published: 30 October 2024
Citation:
Alrafiah A, M.A.F Z, Algothmi K, Mehdar K, Alqahtani SM, Al-Ammari K.
ex
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To determine the serum levels of cytokines, interleukins (IL) and tumor necrosis factor (TNF) in multiple sclerosis (MS) patients and compare with those in healthy individuals. Methods: Twenty-two (22) adult patients with MS and 44 healthy controls, matched for age and gender, and visiting the King Abdulaziz University Hospital, Jeddah, Saudi Arabia were divided into groups I and II, respectively. Serum levels of interferon-gamma (IFN-γ), tumor necrosis factor and interleukins were determined for both groups. Cytokine levels were assessed using Luminex® xMAP® technology in 22 Saudi MS patients and 22 matched healthy controls. Results: There were no significant differences in mean age between Group I (30.14 ± 10.51) and Group II (30.22 ± 5.22) participants (p = 0.982). Furthermore, the levels of IFN-γ, IL-6, IL-8, IL-1β and TNF-α in the serum were significantly higher in Group I patients than in controls (p < 0.0001 for all). Furthermore, a strong positive correlation was found between IFN-γ and IL-8 (r = 0.467, p = 0.028) in MS patients. Conclusion: Patients with MS release significant amounts of inflammatory cytokines, which play a crucial role in understanding the clinical course of MS. These findings enhance the understanding of MS pathophysiology and guide future studies toward developing targeted treatments to mitigate disease progression and improve patients’ quality of life.
Archives
News Updates